About EnzymeRx - Company History
After receiving financing from Pequot Capital Management, EnzymeRx acquired the phase I compound uricase PEG-20 from Polaris Pharmaceuticals. EnzymeRx has been funded to move uricase-PEG 20 through a phase II program in resistant and refractory gout. Please explore our website to learn more about us, about hyperuricemic syndromes including gout and tumor lysis syndrome, and about our product and our planned phase II clinical trial.